Ophthalmic artery chemosurgery reduces recurrent tumors in genetic retinoblastoma
Click Here to Manage Email Alerts
Eyes undergoing ophthalmic artery chemosurgery for hereditary retinoblastoma had fewer new tumors after radiation or systemic chemotherapy than previously believed, according to a study.
The retrospective review included 116 eyes of 81 patients. Forty-one treatment-naïve eyes underwent ophthalmic artery chemosurgery (OAC); 75 eyes underwent OAC after previous treatment with systemic chemotherapy, external beam radiation or both, along with focal techniques.
Mean age at diagnosis was 12.5 years in the treatment-naïve group and 9.1 in the OAC/previous treatment group. Mean follow-up was 22.3 months and 43.8 months in the treatment-naïve group and previous treatment group, respectively.
Study results showed that, among the 41 treatment-naïve eyes, a new tumor was identified in one eye. Among the 75 previously treated eyes, new tumors were identified in six eyes. Focal ablation successfully removed all tumors.
If confirmed by other centers, these findings have the prospect of making changes to present retinoblastoma management, the study authors said.